Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimer’s and Lewy Body Diseases

Abstract

Background: Alzheimer’s disease (AD) and Lewy body disease (LBD) are complex neurodegenerative disorders that have been associated with brain inflammation and impaired neurotransmission. Objective: We aimed to determine concentrations of multiple cytokines, chemokines, and neurotransmitters previously associated with brain inflammation and synapse function in cerebrospinal fluid (CSF) from AD and LBD patients. Methods: We examined a panel of 50 analytes comprising neurotransmitters, cytokines, chemokines, and hormones in CSF in a cohort of patients diagnosed with mild cognitive impairment (MCI), AD, LBD, or non-demented controls (NDC). Results: Among neurotransmitters, noradrenaline (NA) was increased in AD CSF, while homovanillic acid (HVA), a dopamine metabolite, was reduced in both AD and LBD CSF relative to NDC. Six cytokines/chemokines out of 30 investigated were reliably detected in CSF. CSF vascular endothelial growth factor (VEGF) was significantly reduced in LBD patients relative to NDC. Conclusions: CSF alterations in NA, HVA, and VEGF in AD and LBD may reflect pathogenic features of these disorders and provide tools for improved diagnosis. Future studies are warranted to replicate current findings in larger, multicenter cohorts.

Astrocytic Yin Yang 1 is critical for murine brain development and protection against apoptosis, oxidative stress, and inflammation

“…Regardless of the neural cell type, dramatic increases of inflammatory mediators in the astrocytic YY1‐deleted mouse brain could lead to neuronal insults, as proinflammatory cytokines and chemokines contribute to a wide array of neurodegenerative disorders (Ramesh et al, 2013; Dhaiban et al, 2020; Liu et al, 2019; Lourenco et al, 2021). Increased expression levels of multiple chemokines including Cxcl10 may facilitate intercellular communication between glia and neurons (Banisadr et al, 2005).…”

Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans

“…Inclusion criteria for this study were: age > 60 years; absence of other neurological conditions, neurodevelopmental or genetic diseases; native Brazilian Portuguese speakers; formal education ≥ 8 years; no restriction for MRI studies; no severe metabolic disease). All patients were evaluated with the same extensive clinical, neuropsychological, and neuroimaging investigation as described [ 31 – 35 ]. For demographics and biomarker information, see Table 1 .…”

Biomarkers for dementia in Latin American countries: Gaps and opportunities

“…They have reported differences between controls, cognitively impaired patients, AD, and other types of dementia. 46,[53][54][55][56][57] In Colombia, CSF biomarkers were evaluated in young (40-50 years old) carriers of PSEN1 mutation and non-carriers, where clear differences in Aβ were identified between the two groups, which correlates with the clinical progression of this familial variant of AD.…”